|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: DYM |
Gene summary for DYM |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | DYM | Gene ID | 54808 |
| Gene name | dymeclin | |
| Gene Alias | DMC | |
| Cytomap | 18q21.1 | |
| Gene Type | protein-coding | GO ID | GO:0001501 | UniProtAcc | Q7RTS9 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 54808 | DYM | RNA-P6T2-P6T2-4 | Human | Lung | IAC | 2.48e-13 | 4.84e-01 | -0.0121 |
| 54808 | DYM | RNA-P7T1-P7T1-1 | Human | Lung | AIS | 2.91e-08 | 6.95e-01 | -0.0961 |
| 54808 | DYM | RNA-P7T1-P7T1-2 | Human | Lung | AIS | 1.39e-05 | 5.91e-01 | -0.0876 |
| 54808 | DYM | RNA-P7T1-P7T1-3 | Human | Lung | AIS | 3.59e-05 | 6.49e-01 | -0.0822 |
| 54808 | DYM | RNA-P7T1-P7T1-4 | Human | Lung | AIS | 9.20e-09 | 6.59e-01 | -0.0809 |
| 54808 | DYM | C04 | Human | Oral cavity | OSCC | 9.12e-07 | 5.49e-01 | 0.2633 |
| 54808 | DYM | C21 | Human | Oral cavity | OSCC | 6.61e-11 | 3.57e-01 | 0.2678 |
| 54808 | DYM | C30 | Human | Oral cavity | OSCC | 5.33e-19 | 8.66e-01 | 0.3055 |
| 54808 | DYM | C38 | Human | Oral cavity | OSCC | 9.62e-07 | 4.44e-01 | 0.172 |
| 54808 | DYM | C43 | Human | Oral cavity | OSCC | 8.00e-12 | 3.04e-01 | 0.1704 |
| 54808 | DYM | C46 | Human | Oral cavity | OSCC | 5.12e-13 | 3.41e-01 | 0.1673 |
| 54808 | DYM | C51 | Human | Oral cavity | OSCC | 2.44e-04 | 2.29e-01 | 0.2674 |
| 54808 | DYM | C57 | Human | Oral cavity | OSCC | 7.99e-06 | 2.66e-01 | 0.1679 |
| 54808 | DYM | C08 | Human | Oral cavity | OSCC | 9.80e-14 | 3.29e-01 | 0.1919 |
| 54808 | DYM | LN22 | Human | Oral cavity | OSCC | 5.29e-04 | 4.61e-01 | 0.1733 |
| 54808 | DYM | LN46 | Human | Oral cavity | OSCC | 2.42e-10 | 4.56e-01 | 0.1666 |
| 54808 | DYM | EOLP-1 | Human | Oral cavity | EOLP | 8.07e-17 | 5.38e-01 | -0.0202 |
| 54808 | DYM | NEOLP-1 | Human | Oral cavity | NEOLP | 5.08e-06 | 4.25e-01 | -0.0194 |
| 54808 | DYM | NEOLP-2 | Human | Oral cavity | NEOLP | 8.09e-03 | 2.44e-01 | -0.0196 |
| 54808 | DYM | NEOLP-3 | Human | Oral cavity | NEOLP | 5.10e-05 | 2.90e-01 | -0.0191 |
| Page: 1 2 3 4 5 6 7 8 9 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00070304 | Cervix | CC | Golgi organization | 32/2311 | 157/18723 | 2.78e-03 | 1.87e-02 | 32 |
| GO:0060348 | Colorectum | CRC | bone development | 37/2078 | 205/18723 | 1.96e-03 | 1.96e-02 | 37 |
| GO:00070305 | Endometrium | AEH | Golgi organization | 32/2100 | 157/18723 | 5.73e-04 | 5.69e-03 | 32 |
| GO:000703012 | Endometrium | EEC | Golgi organization | 32/2168 | 157/18723 | 9.87e-04 | 8.76e-03 | 32 |
| GO:00070308 | Esophagus | ESCC | Golgi organization | 101/8552 | 157/18723 | 1.78e-06 | 2.10e-05 | 101 |
| GO:00603485 | Esophagus | ESCC | bone development | 115/8552 | 205/18723 | 1.67e-03 | 7.72e-03 | 115 |
| GO:0007030 | Liver | NAFLD | Golgi organization | 36/1882 | 157/18723 | 1.76e-06 | 7.68e-05 | 36 |
| GO:00603481 | Liver | NAFLD | bone development | 33/1882 | 205/18723 | 4.45e-03 | 3.60e-02 | 33 |
| GO:00070301 | Liver | Cirrhotic | Golgi organization | 68/4634 | 157/18723 | 2.57e-07 | 6.41e-06 | 68 |
| GO:00070302 | Liver | HCC | Golgi organization | 99/7958 | 157/18723 | 1.54e-07 | 2.85e-06 | 99 |
| GO:00070303 | Lung | IAC | Golgi organization | 32/2061 | 157/18723 | 4.13e-04 | 6.22e-03 | 32 |
| GO:000703011 | Lung | AIS | Golgi organization | 30/1849 | 157/18723 | 3.09e-04 | 5.63e-03 | 30 |
| GO:000703021 | Lung | MIAC | Golgi organization | 18/967 | 157/18723 | 1.27e-03 | 2.37e-02 | 18 |
| GO:00070307 | Oral cavity | OSCC | Golgi organization | 92/7305 | 157/18723 | 4.96e-07 | 7.27e-06 | 92 |
| GO:00603484 | Oral cavity | OSCC | bone development | 99/7305 | 205/18723 | 4.13e-03 | 1.68e-02 | 99 |
| GO:000703014 | Oral cavity | EOLP | Golgi organization | 37/2218 | 157/18723 | 2.83e-05 | 4.12e-04 | 37 |
| GO:006034812 | Oral cavity | EOLP | bone development | 37/2218 | 205/18723 | 5.84e-03 | 2.95e-02 | 37 |
| GO:006034821 | Oral cavity | NEOLP | bone development | 38/2005 | 205/18723 | 5.28e-04 | 4.64e-03 | 38 |
| GO:000703022 | Oral cavity | NEOLP | Golgi organization | 29/2005 | 157/18723 | 2.40e-03 | 1.53e-02 | 29 |
| GO:00603483 | Prostate | BPH | bone development | 50/3107 | 205/18723 | 2.60e-03 | 1.39e-02 | 50 |
| Page: 1 2 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| DYM | SNV | Missense_Mutation | novel | c.853N>A | p.Leu285Ile | p.L285I | Q7RTS9 | protein_coding | deleterious(0.05) | possibly_damaging(0.883) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| DYM | SNV | Missense_Mutation | novel | c.1209N>G | p.Ile403Met | p.I403M | Q7RTS9 | protein_coding | tolerated(0.05) | probably_damaging(1) | TCGA-C8-A8HP-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | 5-fluorouracil | CR |
| DYM | insertion | Frame_Shift_Ins | novel | c.1483_1484insGCATGCACTGTGTGATACCCTGCATCATCTTGGGATGCCACAG | p.Lys495SerfsTer34 | p.K495Sfs*34 | Q7RTS9 | protein_coding | TCGA-A2-A0D1-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | taxotere | SD | ||
| DYM | insertion | Nonsense_Mutation | novel | c.1662_1663insGGGGCAGATGGTTACAGGGTATGCATATTTGTCAAAACTGGTTGAAC | p.Tyr555GlyfsTer15 | p.Y555Gfs*15 | Q7RTS9 | protein_coding | TCGA-A7-A0CG-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| DYM | insertion | Nonsense_Mutation | novel | c.1597_1598insAGCGAGAACTTAAACCCAGAGTTTGATGATAAGGCCTTTGTTT | p.Arg533GlnfsTer9 | p.R533Qfs*9 | Q7RTS9 | protein_coding | TCGA-BH-A0BD-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | ||
| DYM | SNV | Missense_Mutation | c.496N>C | p.Asp166His | p.D166H | Q7RTS9 | protein_coding | deleterious(0.01) | possibly_damaging(0.905) | TCGA-BI-A0VR-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unknown | Unknown | SD | |
| DYM | SNV | Missense_Mutation | c.1894G>C | p.Glu632Gln | p.E632Q | Q7RTS9 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-C5-A1MJ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| DYM | SNV | Missense_Mutation | c.1390T>G | p.Leu464Val | p.L464V | Q7RTS9 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-C5-A7CL-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | PD | |
| DYM | SNV | Missense_Mutation | c.1034N>T | p.Ser345Phe | p.S345F | Q7RTS9 | protein_coding | tolerated(0.41) | possibly_damaging(0.897) | TCGA-C5-A7UH-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | SD | |
| DYM | SNV | Missense_Mutation | c.1159N>A | p.Glu387Lys | p.E387K | Q7RTS9 | protein_coding | tolerated(0.1) | possibly_damaging(0.802) | TCGA-DG-A2KM-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD |
| Page: 1 2 3 4 5 6 7 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |